Home › Funds › Ikarian Capital, LLC › RLMD

Ikarian Capital, LLC position in RLMD

RELMADA THERAPEUTICS INC · Health Care

Ikarian Capital, LLC reported holding 2,148,359 shares of RLMD (RELMADA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$14.9M, representing 2.39% of its reported portfolio and ranking #8 among its reported holdings. Ikarian Capital, LLC has disclosed RLMD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.15M sh
Reported value held$14.87M
Portfolio Weight2.39%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's RLMD position evolved

Ikarian Capital, LLC first disclosed a stake in RLMD in Q3 2023 at 40,369 shares (US$121K). The position peaked in Q1 2026 at 2,688,359 shares, worth US$18.7M. Across 12 filings, Ikarian Capital, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 2,148,359 shares valued at US$14.9M — a reduction of -540,000 shares quarter over quarter.. Notable position changes include a 4477% increase in Q3 2025 (shares rose 140% over the following quarter), a 66% increase in Q4 2025 (shares rose 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 40.37K $121.11K New
Q4 2023 40.37K $167.13K Hold
Q1 2024 40.37K $187.72K Hold
Q2 2024 40.37K $121.11K Hold
Q3 2024 40.37K $130.79K Hold
Q4 2024 40.27K $20.94K Hold
Q1 2025 40.27K $10.87K Hold
Q2 2025 40.27K $24.17K Hold
Q3 2025 1.84M $3.70M Add
Q4 2025 3.07M $14.82M Add
Q1 2026 2.69M $18.71M Reduce
Q2 2026 2.15M $14.87M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RLMD and 13F data

RLMD (RELMADA THERAPEUTICS INC) is a Health Care company. 76 other funds we track also report a position in RLMD — the largest reported positions include Squadron Capital Management LLC (US$50.9M), Venrock Adviser, LLC (US$47.4M), Spruce Street Capital LP (US$44.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RLMD

All RLMD fund holders →

FAQ

How long has Ikarian Capital, LLC held RLMD?

Ikarian Capital, LLC has disclosed RLMD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Ikarian Capital, LLC's current position in RLMD?

As of Q2 2026, Ikarian Capital, LLC holds 2.15M shares of RLMD (RELMADA THERAPEUTICS INC), valued at $14.87M, representing 2.39% of its reported portfolio and ranking #8.

Has Ikarian Capital, LLC been buying or selling RLMD?

In the latest 13F filing (Q2 2026), Ikarian Capital, LLC reduced its position in RLMD. The position peaked in Q1 2026 at 2.69M shares.

Which other funds hold RLMD?

Other major institutional holders of RLMD include Squadron Capital Management LLC, Venrock Adviser, LLC, Spruce Street Capital LP, among 76 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.